287 related articles for article (PubMed ID: 9949863)
41. Agonist activity of antimigraine drugs at recombinant human 5-HT1A receptors: potential implications for prophylactic and acute therapy.
Newman-Tancredi A; Conte C; Chaput C; Verrièle L; Audinot-Bouchez V; Lochon S; Lavielle G; Millan MJ
Naunyn Schmiedebergs Arch Pharmacol; 1997 Jun; 355(6):682-8. PubMed ID: 9205951
[TBL] [Abstract][Full Text] [Related]
42. Differential distribution of [3H]sumatriptan binding sites (5-HT1B, 5-HT1D and 5-HT1F receptors) in human brain: focus on brainstem and spinal cord.
Castro ME; Pascual J; Romón T; del Arco C; del Olmo E; Pazos A
Neuropharmacology; 1997; 36(4-5):535-42. PubMed ID: 9225278
[TBL] [Abstract][Full Text] [Related]
43. The 5-HT1D receptor antagonist GR-127,935 prevents inhibitory effects of sumatriptan but not CP-122,288 and 5-CT on neurogenic plasma extravasation within guinea pig dura mater.
Yu XJ; Cutrer FM; Moskowitz MA; Waeber C
Neuropharmacology; 1997 Jan; 36(1):83-91. PubMed ID: 9144644
[TBL] [Abstract][Full Text] [Related]
44. Putative role of 5-HT
Segelcke D; Messlinger K
Cephalalgia; 2017 Apr; 37(4):365-371. PubMed ID: 27127104
[TBL] [Abstract][Full Text] [Related]
45. Pre-clinical pharmacology of zolmitriptan (Zomig; formerly 311C90), a centrally and peripherally acting 5HT1B/1D agonist for migraine.
Martin GR
Cephalalgia; 1997 Oct; 17 Suppl 18():4-14. PubMed ID: 9399012
[TBL] [Abstract][Full Text] [Related]
46. The trigemino-vascular system and migraine.
Buzzi MG; Moskowitz MA
Pathol Biol (Paris); 1992 Apr; 40(4):313-7. PubMed ID: 1379707
[TBL] [Abstract][Full Text] [Related]
47. Characterization of LY344864 as a pharmacological tool to study 5-HT1F receptors: binding affinities, brain penetration and activity in the neurogenic dural inflammation model of migraine.
Phebus LA; Johnson KW; Zgombick JM; Gilbert PJ; Van Belle K; Mancuso V; Nelson DL; Calligaro DO; Kiefer AD; Branchek TA; Flaugh ME
Life Sci; 1997; 61(21):2117-26. PubMed ID: 9395253
[TBL] [Abstract][Full Text] [Related]
48. The novel anti-migraine agent rizatriptan inhibits neurogenic dural vasodilation and extravasation.
Williamson DJ; Shepheard SL; Hill RG; Hargreaves RJ
Eur J Pharmacol; 1997 Jun; 328(1):61-4. PubMed ID: 9203569
[TBL] [Abstract][Full Text] [Related]
49. NXN-188, a selective nNOS inhibitor and a 5-HT1B/1D receptor agonist, inhibits CGRP release in preclinical migraine models.
Bhatt DK; Gupta S; Jansen-Olesen I; Andrews JS; Olesen J
Cephalalgia; 2013 Jan; 33(2):87-100. PubMed ID: 23155193
[TBL] [Abstract][Full Text] [Related]
50. 4991W93 inhibits release of calcitonin gene-related peptide in the cat but only at doses with 5HT(1B/1D) receptor agonist activity?
Knight YE; Edvinsson L; Goadsby PJ
Neuropharmacology; 2001 Mar; 40(4):520-5. PubMed ID: 11249961
[TBL] [Abstract][Full Text] [Related]
51. [Suppressing effect of the serotonin 5HT1B/D receptor agonist rizatriptan on calcitonin gene-related peptide (CGRP) concentration in migraine attacks].
Stepień A; Jagustyn P; Trafny EA; Widerkiewicz K
Neurol Neurochir Pol; 2003; 37(5):1013-23. PubMed ID: 15174248
[TBL] [Abstract][Full Text] [Related]
52. Triptans in migraine: a comparative review of pharmacology, pharmacokinetics and efficacy.
Tfelt-Hansen P; De Vries P; Saxena PR
Drugs; 2000 Dec; 60(6):1259-87. PubMed ID: 11152011
[TBL] [Abstract][Full Text] [Related]
53. [Physiopathology of migraine].
Goadsby PJ; Lance JW
Rev Prat; 1990 Feb; 40(5):389-93. PubMed ID: 1968676
[TBL] [Abstract][Full Text] [Related]
54. Cloning and characterization of the guinea pig 5-HT1F receptor subtype: a comparison of the pharmacological profile to the human species homolog.
Adham N; Bard JA; Zgombick JM; Durkin MM; Kucharewicz S; Weinshank RL; Branchek TA
Neuropharmacology; 1997; 36(4-5):569-76. PubMed ID: 9225282
[TBL] [Abstract][Full Text] [Related]
55. Inhibition of noradrenaline release via presynaptic 5-HT1D alpha receptors in human atrium.
Molderings GJ; Frölich D; Likungu J; Göthert M
Naunyn Schmiedebergs Arch Pharmacol; 1996 Feb; 353(3):272-80. PubMed ID: 8692281
[TBL] [Abstract][Full Text] [Related]
56. Targeted 5-HT
Vila-Pueyo M
Neurotherapeutics; 2018 Apr; 15(2):291-303. PubMed ID: 29488143
[TBL] [Abstract][Full Text] [Related]
57. Serotonergic mechanisms of trigeminal meningeal nociception: Implications for migraine pain.
Kilinc E; Guerrero-Toro C; Zakharov A; Vitale C; Gubert-Olive M; Koroleva K; Timonina A; Luz LL; Shelukhina I; Giniatullina R; Tore F; Safronov BV; Giniatullin R
Neuropharmacology; 2017 Apr; 116():160-173. PubMed ID: 28025094
[TBL] [Abstract][Full Text] [Related]
58. Emerging target-based paradigms to prevent and treat migraine.
Silberstein SD
Clin Pharmacol Ther; 2013 Jan; 93(1):78-85. PubMed ID: 23212108
[TBL] [Abstract][Full Text] [Related]
59. Present and future of 5-HT receptor agonists as antimigraine drugs.
Pauwels PJ; John GW
Clin Neuropharmacol; 1999; 22(3):123-36. PubMed ID: 10367177
[TBL] [Abstract][Full Text] [Related]
60. Clinical effects and mechanism of action of sumatriptan in migraine.
Ferrari MD; Saxena PR
Clin Neurol Neurosurg; 1992; 94 Suppl():S73-7. PubMed ID: 1320526
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
